Pharmacology of Sleep Disorders in Children and Adolescents

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages 273-291

  Chhangani, Bantu ^a   Greydanus, Donald E ^b   Patel, Dilip R ^b   Feucht, Cynthia ^c,d  

^a Sleep Medicine Saint Mary's Neuroscience Program   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Borgess Ambulatory Care   (United States)

^d FERRIS STATE UNIVERSITY   (United States)

Author keywords

Insomnia; Medications; Narcolepsy; Obstructive sleep apnea; Pediatric sleep disorders; Restless legs syndrome

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BUDESONIDE; CARBIDOPA PLUS LEVODOPA; CHLORAL HYDRATE; CLONAZEPAM; CLONIDINE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESZOPICLONE; FLUTICASONE PROPIONATE; IRON; KAVA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MELATONIN; METHYLPHENIDATE; MODAFINIL; PLACEBO; PRAMIPEXOLE; RAMELTEON; ROPINIROLE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM TARTRATE;

ABNORMAL DREAMING; ADDICTION; ADOLESCENT; ANOREXIA; ANTICHOLINERGIC SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BEDTIME DOSAGE; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILD; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DIZZINESS; DOPAMINERGIC SYSTEM; DROWSINESS; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; IRON THERAPY; IRRITABILITY; MALAISE; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OXYGEN THERAPY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PSYCHOSIS; REBOUND; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESTLESS LEGS SYNDROME; REVIEW; RHABDOMYOLYSIS; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLEEP DISORDER; STOMACH DISEASE; SUDDEN DEATH; TACHYCARDIA; URINE RETENTION; VOMITING; XEROSTOMIA;

ADOLESCENT; CHILD; HUMANS; PREVALENCE; SLEEP DISORDERS;

EID: 79251550760     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.11.003     Document Type: Review

References (104)

1. American Academy of Sleep Medicine The international classification of sleep disorders 2005, American Academy of Sleep Medicine, Westchester (IL), p. 58-66, 125-32. 2nd edition.
2. Mindell J., Emslie G., Blumer J., et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics 2006, 117:e1223-e1232.
3. Mindell J., Owens J. A clinical guide to pediatric sleep: diagnosis and management of sleep problems in children and adolescents 2003, Lippincott Williams and Wilkins, Philadelphia, p. 1-10.
4. Sadeh A., Raviv A., Gruber R. Sleep patterns and sleep disruptions in school-age children. Dev Psychol 2000, 36(3):291-301.
5. Quine L. Sleep problems in primary school children: comparison between mainstream and special school children. Child Care Health Dev 2001, 27(3):201-221.
6. Stores G. Sleep-wake function in children with neurodevelopmental and psychiatric disorders. Semin Pediatr Neurol 2001, 8(4):188-197.
7. Katari S., Swanson M.S., Trevathan G.D. Persistence of sleep disturbances in preschool children. J Pediatr 1987, 110:642-646.
8. Roberts R.E., Roberts C.R., Duong H.T. Chronic insomnia and its negative consequences for health and functioning of adolescents: a 12-month prospective study. J Adolesc Health 2008, 42(3):294-302.
9. Wiggs L., Stores G. Behavioral treatment for sleep problems in children with severe intellectual disabilities and daytime challenging behavior: effect on mothers and fathers. Br J Health Psychol 2001, 6(Pt 3):257-269.
10. Mindell J.A., Durand V.M. Treatment of childhood sleep disorders: generalization across disorders and effects on family members. J Pediatr Psychol 1993, 18:731-750.
11. Kuhn B.R., Eliott A.J. Treatment efficacy in behavioral pediatric sleep medicine. J Psychosom Res 2003, 54:587-597.
12. Mindell J.A. Empirically supported treatments in pediatric psychology: bedtime refusal and night waking in young children. J Pediatr Psychol 1999, 24:465-481.
13. Stojanovski S.D., Rasu R.S., Balkrishnan R., et al. Trends in medication prescribing for pediatric sleep difficulties in the US outpatient settings. Sleep 2007, 30:1013-1017.
14. Owens J.A., Rosen C.L., Mindell J.A. Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians. Pediatrics 2003, 111:e628-e635.
15. Pediatric Lexi-Drugs: Lexi-Comp, Inc. 2010.
16. Weiss M.D., Wasdell M.B., Bomben M.M., et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry 2006, 45(5):512-519.
17. Giannotti F., Cortesi F., Cerquiglini A., et al. An open-label study of controlled release melatonin in the treatment of sleep disorders in children with autism. J Autism Dev Disord 2006, 36(6):741-752.
18. Sack R.L., Brandes R.W., Kendall A.R., et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000, 343(15):1070-1077.
19. Luboshitzky R., Lavi S., Thuma I., et al. Increased nocturnal melatonin secretion in male patients with hypogonadotropic hypogonadism and delayed puberty. J Clin Endocrinol Metab 1995, 80(7):2144-2148.
20. Sheldon S.H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998, 351(9111):1254. [letter].
21. Sutherland E.R., Martin R.J., Ellison M.C., et al. Immunomodulatory effects of melatonin in asthma. Am J Respir Crit Care Med 2002, 166(8):1055-1061.
22. Turek F.W., Gillette M.U. Melatonin, sleep and circadian rhythms: rationale for the development of specific melatonin agonists. Sleep Med 2004, 5(6):523-532.
23. Erman M., Seiden D., Zammit G., et al. An efficacy, safety and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006, 7(1):17-24.
24. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005, 66(Suppl 9):31-41.
25. Passarella S., Duong M. Diagnosis and treatment of insomnia. Am J Health Syst Pharm 2008, 65:927-934.
26. Schnoes C.J., Kuhn B.R., Workman E.F., et al. Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance. Clin Pediatr (Phila) 2006, 45(3):229-238.
27. Merenstein D., Diener-West M., Halbower A.C., et al. The trial of infant response to diphenhydramine: the TIRED study-a randomized, controlled, patient-oriented trial. Arch Pediatr Adolesc Med 2006, 160(7):707-712.
28. Richardson G.S., Roehrs T.A., Rosenthal L., et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002, 22(5):511-515.
29. Dinndorf P.A., McCabe M.A., Frierdich S. Risk of abuse of diphenhydramine in children and adolescents with chronic illnesses. J Pediatr 1998, 133:293-295.
30. Malvija S., Voepel-Lewis T., Tait A.R. Adverse events and risk factors associated with the sedation of children by nonanesthesiologists. Anesth Anal 1997, 85:1207-1213.
31. Reed M.D., Findling R.L. Overview of current management of sleep disturbances in children: pharmacotherapy. Curr Ther Res Clin Exp 2002, 63(Suppl B):B18-B37.
32. Sheldon S.H. Insomnia in children. Curr Treat Options Neurol 2001, 3:37-50.
33. American Academy of Pediatrics Committee on Drugs and Committee on Environmental Health: use of chloral hydrate for sedation in children. Pediatrics 1993, 92:471-473.
34. Lieberman J.A. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry 2007, 9(1):25-31.
35. Buscemi N., Vandermeer B., Friesen C., et al. The efficacy and safety of drug treatments for chronic insomnia in adults. A meta-analysis of RCTs. J Gen Intern Med 2007, 22(9):1335-1350.
36. Wagner J., Wagner M., Hening W. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998, 32:680-691.
37. Salva P., Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995, 29:142-153.
38. Mohler H., Fritschy J.M., Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002, 300(1):2-8.
39. Zammit G.K., Corser B., Doghramji K., et al. Sleep and residual sedation after administration of zaleplon, zolpidem and placebo during experimental middle of the night awakenings. J Clin Sleep Med 2006, 2:417-423.
40. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 2006, 28:491-516.
41. Stahl S.M. Essential psychopharmacology: the prescriber's guide 2006, Cambridge University Press, Cambridge (UK), Physician's desk reference. 61st edition. Montvale (NJ): Thomson Healthcare Inc; 2007.
42. Prince J.B., Wilens T.E., Biederman J., et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a system chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996, 35:599-605.
43. Ingrassia A., Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders-a case series. Eur Child Adolesc Psychiatry 2005, 14:34-40.
44. Kappagoda C., Schell D.N., Hanson R.M., et al. Clonidine over-dose in childhood: implications of increased prescribing. J Paediatr Child Health 1998, 34:508-512.
45. Walsh J.K., Erman M., Erwin C.L., et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998, 13:191.
46. Drug Facts and Comparisons (database on the Internet). Indianapolis (IN); Facts and comparisons 4.0 Amitriptyline chloride (about 3 screens). Available at:, Accessed August 24, 2010. http://0--online.factsandcomparisons.com.libcat.ferris.edu/MonoDisp.aspx?monoID=fandc-hcp13106&quick=338751/5&search=338751/5isstemmed=true.
47. Balderer G., Borbely A. Effect of valerian on human sleep. Psychopharmacology 1985, 87l:406-409.
48. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products-United States, Germany and Switzerland, 1999-2002. JAMA 2003, 289:36-37.
49. American Academy of Sleep Medicine The international classification of sleep disorders: diagnostic and coding manual 2005, American Academy of Sleep Medicine, Westchester (IL), p. 114-6, 137. 2nd edition.
50. Allen R.P., Pichietti D., Hening W.A., et al. Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
51. Montplaisir J., Boucher S., Poirier G., et al. Clinical polysomnographic and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997, 12:61-65.
52. Picchiette D., Allen R.P., Walters A.S., et al. Restless legs syndrome: prevalence and impact in children and adolescents. The Peds REST Study. Pediatrics 2007, 120(2):253-256.
53. Abetz L., Allen R., Follet A., et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004, 26:925-935.
54. Chervin R.D., Archbold K.H., Dillon J.E., et al. Associations between symptoms of inattention, hyperactivity, restless legs, and periodic leg movements. Sleep 2002, 25:213-218.
55. Chervin R.D., Dillon J.F., Archbold K.H., et al. Conduct problems and symptoms of sleep disorders in children. J Am Acad Child Adolesc Psychiatry 2003, 42:201-208.
56. Picchietti D.L., Stevens H.E. Early manifestations of restless legs syndrome in children and adolescence. Sleep Med 2008, 9(7):770-781.
57. Chesson A.L., Anderson W.M., Littner M., et al. Practice parameters for the treatment of restless legs syndrome and period limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999, 33:961-968.
58. Pichietti M.A., Pichietti D.L. Restless legs syndrome and periodic limb movement disorder in children and adolescents. Semin Pediatr Neurol 2008, 15:91-99.
59. Brodeur C., Montplaisir J., Godbout R., et al. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988, 38:1845-1848.
60. Montplaisir J., Nicolas A., Denesle R., et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999, 52:938-943.
61. Hening W.A., Allen R.P., Earley C.J., et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004, 27:560-583.
62. Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987, 10(1):67-79.
63. Danoff S.K., Grasso M.E., Terry P.B., et al. Pleuropulmonary disease due to pergolide use of restless legs syndrome. Chest 2001, 120(1):313-316.
64. Schade R., Andersohn F., Suissa S., et al. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 2007, 356(1):29-38.
65. Walters A.S., Mandelbaum D.E., Lewin D.S., et al. Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Study Group. Pediatr Neurol 2000, 22(3):182-186.
66. Konofal E., Arnulf I., Lecendreux M., et al. Ropinirole in children with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol 2005, 32:350-351.
67. Kotagal S., Silber M.H. Childhood-onset restless legs syndrome. Ann Neurol 2004, 56:803-807.
68. Allen R.P., Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19:205-213.
69. Earley C.J., Connor J.R., Beard J.L., et al. Abnormalities in CSF concentrations of ferritin and transferring in restless legs syndrome. Neurology 2000, 54:1698-1700.
70. Allen R.P., Barker P.B., Wehrl F., et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56:263-265.
71. Kryger M.H., Otake K., Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med 2002, 3:127-132.
72. Simakajornboon N., Gozal D., Vlasic V., et al. Periodic limb movements in sleep and iron status in children. Sleep 2003, 26:735-738.
73. Garcia-Borreguero D., Larrosa O., de la Liave Y., et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002, 59:1573-1579.
74. Newacheck P.W., Taylor W.R. Childhood chronic illness: prevalence, severity and impact. Am J Public Health 1992, 82(3):364-371.
75. Gislason T., Benediktsdottir B. Snoring, apneic episodes, and nocturnal hypoxemia among children 6 months to 6 years old. An epidemiologic study of lower limit of prevalence. Chest 1995, 107:963-966.
76. Fujioka M., Young L.W., Girdany B.R. Radiographic evaluation of adenoidal size in children: adenoidal naso-pharyngeal ratio. Am J Roentgenol 1979, 133:401-404.
77. Marcus C.L. Sleep-disordered breathing in children. Am J Respir Crit Care Med 2001, 164(1):16-30.
78. Goodwin J.L., Kaemingk K.L., Fregosi R.F., et al. Parasomnias and sleep disordered breathing in Caucasian and Hispanic children-the Tucson children's assessment of sleep apnea study. BMC Med 2004, 2(1):14.
79. Blunden S., Lushington K., Kennedy D. Cognitive and behavioral performance in children with sleep-related obstructive breathing disorders. Sleep Med Rev 2001, 5(6):447-461.
80. Redline S., Tishler P.V., Schluchter M., et al. Risk factors for sleep-disordered breathing in children: associations with obesity, race and respiratory problems. Am J Respir Crit Care Med 1999, 159(5 Pt 1):1527-1532.
81. O'Brien L.M., Mervis C.B., Holbrook C.R., et al. Neurobehavioral correlates of sleep-disordered breathing in children. J Sleep Res 2004, 13(2):165-172.
82. Marcus C.L., Greene M.G., Carroll J.L. Blood pressure in children with obstructive sleep apnea. Am J Respir Crit Care Med 1998, 157(4 Pt 1):1098-1103.
83. Tal A., Lieberman A., Margulis G., et al. Ventricular dysfunction in children with obstructive sleep apnea: a radionuclide assessment. Pediatr Pulmonol 1988, 4:139-143.
84. Section on Pediatric Pulmonology Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002, 109(4):704-712.
85. Massa F., Gonsalez S., Laverty A., et al. The use of nasal continuous positive airway pressure to treat obstructive sleep apnea. Arch Dis Child 2002, 87(5):438-443.
86. Marcus C.L., Carroll J.L., Bamford O., et al. Supplemental oxygen during sleep in children with sleep-disordered breathing. Am J Respir Crit Care Med 1995, 152(4 Pt 1):1297-1301.
87. Brouillette R.T., Manoukian J.J., Ducharme F.M., et al. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. J Pediatr 2001, 138(6):838-844.
88. Mansfield L.E., Diaz G., Posey C.R., et al. Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol 2004, 92(2):240-244.
89. Alexopoulos E.I., Kaditis A.G., Kalampouka E., et al. Nasal corticosteroids for children with snoring. Pediatr Pulmonol 2004, 38(2):161-167.
90. Goldbart A.D., Goldman J.L., Veling M.C., et al. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005, 172:364-370.
91. Taheri S., Zeitzer J.M., Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002, 25:283-313.
92. Challamel M.J., Mazzola M.E., Nevimalova S., et al. Narcolepsy in children. Sleep 1994, 17:S17-S20.
93. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59(10):1553-1562.
94. Mignot E., Lin L., Finn L., et al. Correlates of sleep onset REM periods during the multiple sleep latency test in community adults. Brain 2006, 129:1609-1623.
95. Guilleminault C., Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998, 43:135-142.
96. Morgenthaler T.I., Kapur V.K., Brown T., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30(12):1705-1711.
97. Rogers A.E., Aldrich M.S., Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001, 24(4):385-391.
98. Wisor J.P., Nishino S., Sora I., et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21(5):1787-1794.
99. Swanson J.M., Greenhill L.L., Lopez F.A., et al. Modafinil film-coated tablets in children and adolescents with attention-deficit hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006, 67:137-147.
100. Meoli A., Rosen C., Kristo D., et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med 2005, 1(2):173-187.
101. Wheatley D. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol 2005, 19(1):414-421.
102. Morin A., Jarvis C., Lynch A. Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy 2007, 27(1):89-110.
103. Ryan M., Slevin J. Restless legs syndrome. Am J Health Syst Pharm 2006, 63:1599-1612.
104. Satija P., Ondo W. Restless legs syndrome; pathophysiology, diagnosis and treatment. CNS Drugs 2008, 22(6):497-518.